SUBSCRIBE
SUBSCRIBE

Foresight Diagnostics

IN THE PRESS
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
December 10, 2025
 · 
4 min read
Natera Acquires Foresight Diagnostics
December 5, 2025
 · 
5 min read
Foresight Diagnostics to Participate in the Jefferies Global Healthcare Conference
May 12, 2025
 · 
1 min read
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
February 26, 2025
 · 
7 min read
NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
January 13, 2025
 · 
4 min read
Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review
January 9, 2025
 · 
4 min read
Foresight Diagnostics to Present at 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
 · 
1 min read
Foresight Diagnostics to Present New Data on Foresight CLARITY™ Ultra-Sensitive MRD Detection Across Multiple Studies at the 66th American Society of Hematology Annual Meeting
November 18, 2024
 · 
6 min read
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
August 2, 2024
 · 
10 min read
Foresight Diagnostics Expands Series B Financing to $73.75 Million to Advance the Foresight CLARITY™ MRD Platform
July 30, 2024
 · 
3 min read
JOBS